BioAge Labs, Inc.BIOAEarnings & Financial Report
Altos Labs, Inc. is an American biotechnology research company. Altos Labs' goal is to develop life extension therapies that can halt or reverse the human aging process. Specialized cell therapies based on induced pluripotent stem cells are to be developed for this purpose. Russian-born technology businessman Yuri Milner, along with investors including Jeff Bezos, funded the company in 2021, operations started in 2022.
BIOA Q4 FY2025 Key Financial Metrics
Revenue
$3.1M
Gross Profit
N/A
Operating Profit
$-28.4M
Net Profit
$-25.9M
Gross Margin
N/A
Operating Margin
-923.4%
Net Margin
-842.9%
YoY Growth
N/A
EPS
$-0.72
BioAge Labs, Inc. Q4 FY2025 Financial Summary
BioAge Labs, Inc. reported revenue of $3.1M for Q4 FY2025, with a net profit of $-25.9M (-842.9% margin).
Key Financial Metrics
| Total Revenue | $3.1M |
|---|---|
| Net Profit | $-25.9M |
| Gross Margin | N/A |
| Operating Margin | -923.4% |
| Report Period | Q4 FY2025 |
BioAge Labs, Inc. Annual Revenue by Year
BioAge Labs, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.0M).
BioAge Labs, Inc. Quarterly Revenue & Net Profit History
BioAge Labs, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.1M | — | $-25.9M | -842.9% |
| Q3 FY2025 | $2.1M | — | $-20.2M | -982.0% |
| Q2 FY2025 | $2.4M | — | $-21.6M | -894.0% |
| Q1 FY2025 | $1.5M | — | $-12.9M | -891.0% |
| Q3 FY2024 | $0 | — | $-23.4M | N/A |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $1.5M | $2.4M | $2.1M | $3.1M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Assets | $337.4M | $343.8M | $322.1M | $305.1M | $294.9M |
| Liabilities | $23.6M | $30.7M | $27.4M | $27.6M | $22.8M |
| Equity | $313.7M | $313.2M | $294.8M | $277.5M | $272.1M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-17.4M | $-20.0M | $-16.0M | $-28.3M |